Mark Vignola serves as the Chief Financial Officer at Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver diseases and oncology. In this pivotal role, he oversees the company's financial strategy, including capital raising, investor relations, and operational finance, ensuring alignment with Terns' mission to advance novel treatments for non-alcoholic steatohepatitis (NASH) and other serious conditions. Vignola joined Terns in 2020, bringing extensive expertise in biotechnology finance that has been instrumental in guiding the company through its initial public offering (IPO) in 2021 and subsequent funding rounds, bolstering its pipeline of small-molecule drug candidates. Prior to Terns, Vignola held key financial leadership positions at several prominent biotech firms, including as CFO at Applied Molecular Transport and as Vice President of Corporate Development at Anacor Pharmaceuticals, where he played a critical role in its $5.2 billion acquisition by Pfizer in 2016. His career also includes significant experience in investment banking, having worked at firms like Bank of America Merrill Lynch, where he advised on mergers, acquisitions, and equity offerings in the life sciences sector. Vignola's achievements include raising over $1 billion in capital across various companies and contributing to successful drug development programs that have advanced from preclinical stages to commercialization. Educated at the University of Pennsylvania's Wharton School with an MBA in Finance and at Boston College with a BS in Finance, Vignola is recognized for his strategic acumen and ability to navigate complex regulatory and market environments. At Terns, he continues to drive financial discipline while fostering collaborations that accelerate research and development, positioning the company as a leader in addressing unmet medical needs in metabolic and oncologic diseases.